Standout Papers
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2017)
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (2012)
- Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States (2011)
- Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up Study (2010)
- Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation (2017)
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial (2017)
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease (2018)
- Broadly neutralizing antibodies abrogate established hepatitis C virus infection (2014)
- Liver Transplantation 2023: Status Report, Current and Future Challenges (2023)
- Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance (2023)
- Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis (2024)
Immediate Impact
2 by Nobel laureates 4 from Science/Nature 262 standout
Citing Papers
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
2024 Standout
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
2023 Standout
Works of Michael Charlton being referenced
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Michael Charlton | 18908 | 12598 | 5229 | 6056 | 247 | 24.5k | |
| Linda D. Ferrell | 12777 | 10128 | 6471 | 2976 | 222 | 21.3k | |
| Kris V. Kowdley | 19511 | 14089 | 5453 | 4983 | 446 | 28.4k | |
| Oscar W. Cummings | 10984 | 4622 | 5661 | 3874 | 198 | 19.0k | |
| Richard K. Sterling | 15359 | 13320 | 4301 | 2821 | 315 | 20.0k | |
| Manal F. Abdelmalek | 12684 | 5599 | 2303 | 6079 | 204 | 16.1k | |
| Naga Chalasani | 25932 | 13934 | 6535 | 9759 | 485 | 35.8k | |
| Alastair D. Burt | 11893 | 8321 | 3121 | 3744 | 232 | 17.9k | |
| Geoffrey C. Farrell | 19440 | 9801 | 3649 | 6780 | 213 | 25.5k | |
| Emmanuel Tsochatzis | 11637 | 9154 | 3273 | 2441 | 298 | 15.1k | |
| Stephen H. Caldwell | 14013 | 10002 | 4144 | 4130 | 256 | 18.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...